Parasitic worms help Professor Clarissa Prazeres da Costa and her team better understand the human immune system in order to find solutions to global health problems.
Why do blood clots develop in the first place—and why do they tend to recur? LMU researcher Konstantin Stark believes that the answers lie in the immune system.
At RCI, the Regensburg Center for Interventional Immunology, international research groups develop immunotherapies and cellular therapies in order to help treating patients suffering from tumors, chronic inflammation or autoimmunity.
From junior research group leader to full professor and spokesperson of the Research Center for Infectious Diseases (ZINF) at the University of Würzburg. This is the scientific career path of Cynthia Sharma.
Detect influenza viruses quickly and easily with chewing gum or a lollipop: researchers from Würzburg, Braunschweig and Cologne demonstrate with a new diagnostic tool how this works.
It is well established that gut microbiome composition plays a pivotal role in human health – yet the precise connections are still not fully elucidated. Researchers at the Technical University of Munich (TUM) have moved a step closer to understanding these complex interactions: they have identified a cellular mechanism that alters the gut microbiome in a way that promotes cancer. An analysis of patient data shows that the findings also apply to humans.
Six researchers from Würzburg have been awarded prestigious grants for their projects: the European Research Council's Starting Grants are worth €1.5 million each.
A study from Würzburg reveals: pox viruses have developed a unique strategy to rapidly multiply after infecting a host cell. The findings uncover a previously unknown role for a well-known molecule and may serve as a starting point for the development of new antiviral agents.
In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of Augsburg have provided reliable evidence for a link between chronic inflammatory diseases and the development of tumours in the digestive tract. The results were recently published in eClinicalMedicine, which is part of the Lancet Group.
Immunotherapy using CAR T cells is finding ever more applications. In addition to their use in the treatment of blood and lymphatic cancers, CAR T-cells are now also being investigated for solid tumors and various autoimmune diseases. With the growing number of indications and patients, the issue of side effects associated with this innovative therapy is becoming even more pressing. A team led by Dr. Kai Rejeski from the LMU University Hospital Munich has proposed a new strategy in the renowned journal Nature Medicine to systematically and more rapidly address novel and emerging side effects. The strategy is called IAGO – like the villain in Shakespeare’s Othello.
